干扰素与细胞抑制药物联合治疗晚期结直肠癌
Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer.
作者信息
Klein H O, Golbach G, Voigt P, Coerper C, Bernhardt C
机构信息
Department of Internal Medicine, University of Cologne, Federal Republic of Germany.
出版信息
J Cancer Res Clin Oncol. 1991;117 Suppl 4(Suppl 4):S214-20. doi: 10.1007/BF01613230.
Abstract
Three phase I/II trials were performed in patients with metastatic colorectal cancer using immunochemotherapy--a combination of recombinant interferon beta and gamma with low doses of cytostatic drugs. The third regimen, consisting of a cytostatic component containing 5-fluorouracil plus carboplatin plus mitomycin C besides the interferons, produced a high remission rate of 47%: 14/30 patients responded. The tolerability of this protocol was good and it could be administered on an out-patient basis.
摘要
针对转移性结直肠癌患者开展了三项I/II期试验，采用免疫化疗——重组干扰素β和γ与低剂量细胞毒性药物联合使用。第三种方案除干扰素外，还包含含有5-氟尿嘧啶、卡铂和丝裂霉素C的细胞毒性成分，缓解率高达47%：30例患者中有14例有反应。该方案耐受性良好，可在门诊给药。
相似文献
1
Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer.干扰素与细胞抑制药物联合治疗晚期结直肠癌
J Cancer Res Clin Oncol. 1991;117 Suppl 4(Suppl 4):S214-20. doi: 10.1007/BF01613230.
2
Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.高剂量亚叶酸钙和干扰素α-2b对晚期结直肠癌患者5-氟尿嘧啶的双重调节作用：每周给药的I期和II期研究
J Cancer Res Clin Oncol. 1994;120(5):314-8. doi: 10.1007/BF01236390.
3
FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial.FOLFIRINOX-3联合贝伐单抗（bFOLFIRINOX3）治疗化疗难治性转移性结直肠癌：一项多中心II期试验
Future Oncol. 2025 Mar;21(6):699-706. doi: 10.1080/14796694.2025.2461446. Epub 2025 Feb 6.
4
A systematic overview of chemotherapy effects in colorectal cancer.结直肠癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):282-308. doi: 10.1080/02841860151116367.
5
Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.多柔比星联合异环磷酰胺加重组人粒细胞巨噬细胞集落刺激因子治疗晚期成人软组织肉瘤：欧洲癌症研究与治疗组织软组织和骨肉瘤组II期研究的初步结果
J Cancer Res Clin Oncol. 1991;117 Suppl 4(Suppl 4):S193-7. doi: 10.1007/BF01613226.
6
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.基于吉西他滨的晚期胆管癌化疗
Cochrane Database Syst Rev. 2018 Apr 6;4(4):CD011746. doi: 10.1002/14651858.CD011746.pub2.
7
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.赞布替尼联合化疗作为HER2阳性晚期胃食管腺癌患者的一线治疗：一项多中心、单臂、2期研究的主要结果
Lancet Oncol. 2025 May 30. doi: 10.1016/S1470-2045(25)00287-6.
8
Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer.5-氟尿嘧啶、亚叶酸钙和齐多夫定治疗转移性结直肠癌患者的II期研究。
J Cancer Res Clin Oncol. 1996;122(9):554-8. doi: 10.1007/BF01213552.
9
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.伊立替康、奥沙利铂和雷替曲塞用于治疗晚期结直肠癌：系统评价与经济学评估
Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. doi: 10.3310/hta12150.
10
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.奥氮平5毫克联合三联止吐药用于含蒽环类方案治疗乳腺癌患者的总体疗效和安全性：一项3期、双盲、随机、安慰剂对照试验。
Lancet Oncol. 2025 Jun 17. doi: 10.1016/S1470-2045(25)00233-5.
引用本文的文献
1
Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results.肝动脉内灌注与瘤内注射化疗联合治疗晚期肝细胞癌伴动门脉或动静脉分流患者：初步结果
Korean J Hepatol. 2011 Jun;17(2):120-9. doi: 10.3350/kjhep.2011.17.2.120.
本文引用的文献
1
Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients.247例癌症患者中具有自然杀伤（NK）细胞功能的颗粒淋巴细胞水平降低。
Ann Surg. 1983 Aug;198(2):192-9. doi: 10.1097/00000658-198308000-00014.
2
[Biological effect of recombined leukocyte alpha-2-interferon in metastasizing colorectal cancers].[重组白细胞α-2干扰素在转移性结直肠癌中的生物学效应]
Dtsch Med Wochenschr. 1984 May 18;109(20):779-82. doi: 10.1055/s-2008-1069272.
3
4
Heterogeneity of natural killer lymphocyte abnormalities in colon cancer patients.结肠癌患者自然杀伤淋巴细胞异常的异质性。
Surgery. 1984 Jan;95(1):63-70.
5
Cytolytic activity of interferon-gamma and its synergism with 5-fluorouracil.干扰素-γ的细胞溶解活性及其与5-氟尿嘧啶的协同作用。
Int J Cancer. 1984 Oct 15;34(4):495-500. doi: 10.1002/ijc.2910340411.
6
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.与免疫反应相关的新蝶呤产生。主要在γ干扰素的控制下从巨噬细胞释放。
J Exp Med. 1984 Jul 1;160(1):310-6. doi: 10.1084/jem.160.1.310.
7
Potentiation of lymphocyte natural killing by mixtures of alpha or beta interferon with recombinant gamma interferon.α或β干扰素与重组γ干扰素混合物对淋巴细胞自然杀伤作用的增强
Infect Immun. 1983 Apr;40(1):35-8. doi: 10.1128/iai.40.1.35-38.1983.
8
Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons.大肠杆菌衍生的人α、β和γ干扰素的协同抗病毒和抗增殖活性。
J Virol. 1984 Feb;49(2):490-6. doi: 10.1128/JVI.49.2.490-496.1984.
9
In vitro and in vivo studies on potentiation of cytotoxic effects of anticancer drugs or cobalt 60 gamma ray by interferon on human neoplastic cells.关于干扰素对人肿瘤细胞增强抗癌药物或钴60γ射线细胞毒性作用的体外和体内研究。
Cancer. 1984 Nov 15;54(10):2262-7. doi: 10.1002/1097-0142(19841115)54:10<2262::aid-cncr2820541033>3.0.co;2-n.
10
Potentiation of T-lymphocyte function by bleomycin.
Immunopharmacology. 1984 Apr;7(2):109-13. doi: 10.1016/0162-3109(84)90060-2.
Zotero 插件